Aptuit prefers to operate behind the scenes. A pharmaceutical services company, Aptuit offers a range of support services to biotech and other drug development companies, including early- to late-stage development of pharmaceutical ingredients, clinical studies support, information systems development, project management, and consulting services. The company operates from more than a dozen offices in North America, Europe, and the Asia-Pacific region and serves companies of all sizes. Aptuit was founded in 2004; private equity firm Welsh, Carson, Anderson & Stowe holds a significant ownership stake in the company.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company is developing a portfolio consisting of its four product candidates, including pimavanserin, which is in Phase III development for the treatment of Parkinson’s disease psychosis. In addition, the Company has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, Inc., and ACP-106 in IND-track development. The Company’s product candidates include Pimavanserin, AGN-XX/YY, AC-262271 and ACP-106. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark.

Minrad International, Inc. company, through its Minrad Inc. subsidiary, develops real-time image guidance products used in anesthesiology, orthopedics, neurosurgery, and interventional radiology. The company's technologies, including its SabreSource system, improve accuracy in surgical procedures and reduce radiation exposure. Minrad also makes handheld surgical instruments and generic inhalation anesthetics used in human and veterinary surgeries. In addition, the company is developing other anesthetic drugs that relieve patients' pain during surgery without the loss of consciousness. Minrad belongs to Indian pharma firm Piramal Healthcare.

Omnicare Clinical Research is a contract research organization (CRO) offering drug development services, from Phase I to Phase IV clinical trials, to drug and medical device companies worldwide. A unit of nursing home pharmacy operator Omnicare, the CRO has special expertise in the area of geriatrics research and takes advantage of its parent's access to geriatric patient populations and investigators. However, the unit also provides support in numerous other therapeutic areas, including cardiovascular, dermatology, metabolism, and infectious disease. Services include patient and investigator recruitment, drug packaging and distribution, clinical trials management, and medical writing.

Genmab was founded in 1999. Genmab analyzes genomes in its lab. The biotech company creates and develops human antibodies to treat such conditions as lymphoma and other cancers, as well as autoimmune and inflammatory diseases. It has assembled a portfolio of products under its HuMax brand that are in different stages of development, ranging from pre-clinical to late-stage trials. In addition to developing its HuMax products, Genmab is working to create products for conditions such as infectious diseases and vascular conditions. The company has licensing and development partnerships with several international pharmaceutical and biotech companies including GlaxoSmithKline, Amgen, Medarex, and Roche.

PRA International knows it takes more than laboratory research to get drugs approved. The company, a clinical research organization (CRO), provides an array of drug development services to pharmaceutical and biotech companies around the world. Services the company offers include clinical trials management, database development, and regulatory filings preparation. PRA's clients are engaged in most major therapeutic areas, but the firm's particular strengths lie in oncology, central nervous system disorders, cardiovascular disease, allergy and respiratory disorders, and infectious disease. The company is owned by private equity firm Genstar Capital.

Quidel Corporation was founded in 1979 and is based in San Diego, California. Quidel Corporation is engaged in the development, manufacturing and marketing of rapid diagnostic solutions for decentralized applications, including professional point-of-care (POC) in infectious diseases, reproductive and women’s health. The Company focuses on POC testing solutions specifically developed for the physician office lab (POL) and acute care markets globally. It sells its products to professionals for use in physician offices, hospitals, clinical laboratories and wellness screening centers. Its POC testing solutions are designed to provide specialized results that meet two value criteria that the Company has branded as Quidel Value Build (QVB). The Company provides rapid POC and other diagnostic tests under brand names, including QuickVue, QuickVue+, QuickVue Advance, Metra, Quidel and MicroVue. The Company markets its products in the United States through a network of national and regional distributors, supported by a direct sales force.

The biopharmaceutical company develops cholesterol-lowering drugs for the treatment of cardiovascular and metabolic disease, specifically targeting elevated LDL (low-density lipoprotein, also known as "bad" cholesterol) levels. Its flagship products - experimental drugs AEGR-733 and AEGR-427 - are MTP (microsomal triglyceride transfer protein) inhibitors, drugs which block a protein that incites cholesterol production in the liver and intestine. Cutting LDL levels may add years to patients' lives but must be weighed against potential side effects such as fat accumulation in the liver, which can lead to inflammation, scarring, and cirrhosis.

Shionogi & Co. wants to kill it like a shinobi (i.e. ninja) in the night. The Japanese drug firm is a leading maker of antibiotics in its home country, with a full lineup of oral and injectable anti-infectives. It has been expanding its pipeline and its portfolio of marketed products to encompass other therapeutic areas as well, with programs in metabolic conditions and pain management. Through partnerships with large global firms, it owns Japanese market rights to some big name drugs, including AstraZeneca's blood pressure drug Crestor (which Shionogi helped develop); Purdue Pharma's pain therapy OxyContin; and Merck & Co. allergy medication Claritin.

Sangamo BioSciences, Inc. was founded in 1995 and is based in Richmond, California. Sangamo BioSciences, Inc. engages in the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs can be engineered to make ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off; and ZFP nucleases, proteins that enable to modify DNA sequences in various ways. The company’s ZFP Therapeutic, SB-509, a plasmid formulation of a ZFP TF activator of the vascular endothelial growth factor-A (VEGF-A) gene, which is in three Phase 2 clinical trials for the treatment of diabetic neuropathy and one Phase 2 trial for amyotrophic lateral sclerosis. It also develops SB-728-T, which is in the Phase 1 clinical trial for the treatment of HIV/AIDS. In addition, Sangamo BioSciences, Inc. involves in the preclinical development programs of ZFP therapeutics that focus on spinal cord injury, stroke, traumatic brain injury, neuropathic pain, and Parkinson's disease. Additionally, the company has research-stage programs in X-linked severe combined immunodeficiency, hemophilia, and hemoglobinopathies. It has license agreements with companies, including Dow AgroSciences, LLC;Sigma-Aldrich Corporation; Pfizer, Inc.; Genentech Inc.; and Medarex, Inc., as well as has research agreements with Amgen Inc., Novo Nordisk Inc., Novartis A/G, and Kirin Brewery Company.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.